ClinicalTrials.gg
CompletedNCT02183688Updated Jul 8, 2014

Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients

A Phase 3 interventional study of Low dose ASA and High dose ASA in Migraine Disorders, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,889
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing acetaminophen in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Migraine Disorders.

Enrollment
Largest of 15
1,889 · median 200
Started
1998
the only one that year
Phase 3
3 of 15
none open now
Registered
6th of 15
by date
Lead sponsor
1 of 15
Boehringer Ingelheim

Among the 15 studies testing acetaminophen in Migraine Disorders, this one has the largest enrollment, is the only one that started in 1998, is one of 3 in phase 3, and was the 6th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

1 of the 15 studies testing acetaminophen in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing acetaminophen in Migraine Disorders, or all of them as a file.
02

Study summary

To confirm the combination rationale for the combination of ASA + paracetamol + caffeine compared with the combination of ASA + paracetamol and the individual substances ASA, paracetamol, caffeine, and placebo administered orally to headache patients for two headache episodes

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male out-patients aged between 18 and 65 years
  2. Diagnosis: Headache

    1. Tension type headache according to international headache society (IHS) Headache Classification 2.1 (2.1.1 and 2.1.2) and/or
    2. Migraine according to IHS Headache Classification 1.1, 1.2.1 or
    3. Either a) or b), but cannot be distinctly classified
  3. The patient normally treats his/her headache successfully with non-prescription analgesics
  4. He/She has been suffering from headache for 12 months at least
  5. The headache first occurred before the age of 50 years
  6. During the previous three months, the patient has suffered from headache twice a month at least
  7. according to §§ 40, 41 of the german medicines act and Good Clinical Practice (GCP)
  8. The patient seems likely to comply

Exclusion criteria

Exclusion Criteria:

  1. The patient treats his/her headache with prescription-only analgesics or migraine remedies
  2. The patient requires higher single doses of non-prescription analgesics to treat his/her headache than indicated in the patient information leaflet (e.g. more than 2 tablets of Thomapyrin tablets)
  3. The patient normally treats his/her headache with non-prescription analgesics in effervescent tablet form
  4. The patient normally takes his/her non-prescription analgesics immediately at the onset of the first signs of a headache episode
  5. Headache occurs on more than 10 days per month
  6. The typical, untreated headache normally lasts less than 4 hours without treatment
  7. Women with a close association between the occurrence of headache and menstruation (menstrual migraine)
  8. Concomitant treatment with prescription-only and/or non-prescription analgesics
  9. Previous or concomitant treatment with antidepressants or antipsychotic medicines (previous treatment = within the previous 4 weeks)
  10. Previous or concomitant treatment with anti-rheumatic or anti-inflammatory drugs that may influence the headache symptoms (previous treatment = within the previous 4 days)
  11. Treatment of concomitant illnesses with drugs containing ASA (above a daily dose of 100 mg per day), paracetamol or caffeine (e.g. for feverish common cold, etc.)
  12. Migraine prophylaxis or administration of drugs, indicated for any other reasons that influence headache symptoms, e.g.

    Propanolol, Metoprolol, Flunarizine, Cyclandelate, Valproic acid, Serotonin antagonists (pizotifen, methysergide, lisuride), Ergotamine, Dihydroergotamine, Benzodiazepines, Magnesium, Monoamine oxidase inhibitors

  13. Concomitant treatments with anti-emetics
  14. Drug abuse connected with the headache (defined as the administration of analgesics or other drugs for the treatment of acute headache on more than 10 days per month)
  15. Alcohol or drug abuse as defined by (DSM-IV)
  16. Pregnancy and lactation
  17. Gastrointestinal ulcers
  18. Pathologically increased bleeding tendency
  19. Glucose-6-phosphate dehydrogenase deficiency
  20. to paracetamol, caffeine, ASA, salicylates, and other anti-inflammatory/anti-rheumatic agents or other allergenic substances that are relevant to the clinical trial
  21. Bronchial asthma
  22. Concomitant treatment with anticoagulants (e.g. coumarin derivates, heparin)
  23. chronic or recurrent gastrointestinal symptoms
  24. Clinically relevant liver disorders
  25. Clinically relevant pre-existing renal damage
  26. Gilbert's syndrome
  27. Not successfully treated hyperthyroidism
  28. Simultaneous participation in another clinical trial
  29. Participation in another clinical trial within 4 weeks of entering this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,889 participants (actual)

Study arms

  • Experimental
    ASA + paracetamol + caffeine

    Drug: Low dose ASA · Drug: Low dose paracetamol · Drug: Caffeine

  • Active comparator
    ASA + paracetamol

    Drug: Low dose ASA · Drug: Low dose paracetamol

  • Active comparator
    ASA

    Drug: High dose ASA

  • Active comparator
    Paracetamol

    Drug: High dose paracetamol

  • Active comparator
    Caffeine

    Drug: Caffeine

  • Placebo comparator
    Placebo

    Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Calculated time to 50% pain relief, based on the pain intensity evaluated on a visual analogue scale (VAS)

    Time frame: 30 min., 1, 2, 3 and 4 hours after administration of the study medication

Secondary outcomes

  1. Percentage of patients with 50 % pain relief, evaluated on a VAS

    Time frame: At least 2 hours after administration of the study medication

  2. Percentage of patients with 50 % pain relief, evaluated on a VAS

    Time frame: At least 30 min., 1, 3, and 4 hours after administration of the study medication

  3. Pain intensity, evaluated on a VAS

    Time frame: 30 min., 1, 2, 3 and 4 hours after administration of the study medication

  4. Ratio of weighted sum of pain intensity difference scores to maximum achievable sum of pain intensity differences (%SPIDweighted), evaluated on a VAS

    Time frame: Up to the end of the study

  5. Extent of impairment of daily activities, evaluated on a 4-grade verbal scale (VRS)

    Time frame: Before, 30 min., 1, 2, 3 and 4 hours after administration of study drug

  6. Duration of headache

    Time frame: Up to 48 hours after onset of each headache episode

  7. Global assessment of efficacy by the patient, evaluated on a 4-grade VRS

    Time frame: Within 12 hours after study drug administration

  8. Global assessment of tolerability by the patient, evaluated on a 4-grade VRS

    Time frame: Within 12 hours after study drug administration

  9. Number of patients with adverse events

    Time frame: Up to the end of the study

  10. Global assessment of tolerability by the investigator, evaluated on a 4-grade VRS

    Time frame: After each administration of study drug during the treatment phase

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1998 and a primary completion of Jan 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 8, 2014
Start
Sep 1998
Primary completionActual
Jan 2003
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183688
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Sep 1998
Primary completion
Jan 2003
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Acetaminophen · Caffeine

Start the discussion